Abcellera Biologics Inc (ABCL)

Currency in USD
4.340
+0.100(+2.36%)
Closed·
After Hours
4.450+0.110(+2.53%)
·
ABCL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ABCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.1304.380
52 wk Range
1.8915.820
Key Statistics
Prev. Close
4.24
Open
4.275
Day's Range
4.13-4.38
52 wk Range
1.891-5.82
Volume
3.62M
Average Volume (3m)
6.19M
1-Year Change
45.21%
Book Value / Share
3.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.143
Upside
+110.66%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Abcellera Biologics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Abcellera Biologics Inc Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Abcellera Biologics Inc SWOT Analysis


Innovative Platform
AbCellera's tech-enabled antibody discovery platform shows promise in drug development, validated through COVID-19 treatments and strategic partnerships.
Financial Strength
With $1 billion in liquidity, AbCellera is well-positioned for extended operations and strategic investments, despite recent downward estimate revisions.
Explore Partnerships
Collaborations with Biogen and Viking/ArrowMark highlight AbCellera's potential for long-term revenue growth and expanded therapeutic applications.
Future Prospects
Analyst targets range from $7 to $12, reflecting optimism about AbCellera's internal pipeline development and manufacturing capabilities amid industry changes.
Read full SWOT analysis

Abcellera Biologics Inc Earnings Call Summary for Q3/2024

  • Q3 2024 revenue steady at $7M; net loss of $51M due to increased R&D expenses and $32M non-cash impairment charge
  • CTA filings for ABCL635 and ABCL575 expected in Q2 2025; market potential for ABCL635 exceeds $2B
  • Strong liquidity with $670M cash, $210M government funding; sufficient for next 3 years and 2-3 new development candidates annually
  • Expanded partnership with Eli Lilly; GMP manufacturing facility operational in 2025; portfolio review to conclude by December 2023
  • Optimistic outlook for lead atopic dermatitis asset; growing excitement around T-cell engagers (TCEs) in cancer therapies
Last Updated: 05/11/2024, 09:10
Read Full Transcript

Compare ABCL to Peers and Sector

Metrics to compare
ABCL
Peers
Sector
Relationship
P/E Ratio
−7.5x−2.5x−0.5x
PEG Ratio
0.680.080.00
Price/Book
1.2x1.1x2.6x
Price / LTM Sales
54.8x1.9x3.3x
Upside (Analyst Target)
107.4%57.2%45.1%
Fair Value Upside
Unlock31.0%7.4%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.143
(+110.66% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.14 / -0.13
Revenue / Forecast
9.95M / 11.98M
EPS Revisions
Last 90 days

ABCL Income Statement

People Also Watch

13.84
OSCR
+1.91%
15.800
ZETA
+4.77%
51.380
ASTS
-2.06%
16.480
IREN
+7.01%
164.90
CRCL
-1.90%

FAQ

What Stock Exchange Does Abcellera Biologics Trade On?

Abcellera Biologics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Abcellera Biologics?

The stock symbol for Abcellera Biologics is "ABCL."

What Is the Abcellera Biologics Market Cap?

As of today, Abcellera Biologics market cap is 1.27B.

What Is Abcellera Biologics's Earnings Per Share (TTM)?

The Abcellera Biologics EPS (TTM) is -0.57.

When Is the Next Abcellera Biologics Earnings Date?

Abcellera Biologics will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is ABCL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Abcellera Biologics Stock Split?

Abcellera Biologics has split 0 times.

How Many Employees Does Abcellera Biologics Have?

Abcellera Biologics has 596 employees.

What is the current trading status of Abcellera Biologics (ABCL)?

As of 05 Aug 2025, Abcellera Biologics (ABCL) is trading at a price of 4.34, with a previous close of 4.24. The stock has fluctuated within a day range of 4.13 to 4.38, while its 52-week range spans from 1.89 to 5.82.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.